Proactive Investors - Run By Investors For Investors

AstraZeneca sells off US rights to children’s lung disease treatment for up to US$2bn

Over the past couple of weeks, the FTSE 100 drugs giant has sold off the rights to three asthma and hay fever treatments, one heartburn medicine, an arthritis drug and now a lung disease treatment
sneezing baby
130 AstraZeneca employees will move to Sobi as part of the deal

AstraZeneca PLC’s (LON:AZN) recent spate of divestments continued on Tuesday as the pharma giant announced it has struck a deal to sell off the US rights to its Synagis lung disease treatment for almost US$2bn.

The FTSE 100 company will receive US$1.5bn in cash and shares upfront from Stockholm-based rare diseases specialist Swedish Orphan Biovitrum (Sobi) for the drug. On top of that, Astra also stands to receive up to another US$470mln in sales-related payments.

READ: Astra sells off remaining rights to three asthma and hay fever treatments for US$370mln

Synagis, which has generated just shy of US$120mln in pre-tax profits for AstraZeneca so far this year, helps to prevent serious lower respiratory tract infections caused by respiratory syncytial virus in premature babies or toddlers with chronic lung or heart conditions.

As part of the deal, Sobi will also have the right to participate in AstraZeneca's share of US profits and losses related to potential new medicine MEDI8897.

Like Synagis, MEDI8897 is being developed for the prevention of LRTI caused by RSV in at-risk infants, but it has the potential benefit of only needing to be administered once during the RSV season, whereas Synagis is a once-monthly injection.

READ: Astra offloads rights to two more ‘non-core’ drugs for US$1bn

“We continue to streamline our portfolio, allowing AstraZeneca to allocate resources more effectively, while Sobi's focus on Synagis will enable infants in the US to continue benefiting from this important treatment,” said chief executive Pascal Soriot.

“Meanwhile, the successful development and commercialisation of MEDI8897 remains important for AstraZeneca.”

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
A man's knee pain is highlighted with a red area that points to inflammation
January 23 2019
The injectable PPS trial has had a clinically meaningful and statistically significant result in patients with arthritic knee pain.
consumer health segment overview
January 11 2019
The company sells clinically validated anti-ageing products for hair, skin and body.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use